{"id":"prograf-soc","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nephrotoxicity (renal dysfunction)"},{"rate":"30-50","effect":"Hypertension"},{"rate":"20-30","effect":"Hyperglycemia"},{"rate":"10-25","effect":"Neurotoxicity (tremor, headache)"},{"rate":"15-30","effect":"Infections"},{"rate":"10-20","effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a key phosphatase required for T-cell receptor signaling and IL-2 production. By blocking calcineurin, the drug prevents the transcription of cytokine genes essential for T-cell proliferation, thereby suppressing the immune response that would otherwise reject transplanted organs.","oneSentence":"Prograf (tacrolimus) inhibits calcineurin phosphatase, suppressing T-cell activation and proliferation to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:58.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant recipients"},{"name":"Prevention of organ rejection in heart transplant recipients"},{"name":"Prevention of organ rejection in liver transplant recipients"}]},"trialDetails":[{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT07359859","phase":"PHASE2","title":"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-20","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT06291103","phase":"PHASE2, PHASE3","title":"Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03-01","conditions":"Kidney Transplant Rejection","enrollment":290},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT07104799","phase":"PHASE1","title":"Momelotinib During and After HCT in Myelofibrosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Myelofibrosis, Hematopoietic Cell Transplantation (HCT)","enrollment":28},{"nctId":"NCT05432765","phase":"NA","title":"AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-12","conditions":"Kidney Transplant Rejection","enrollment":34},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT07290777","phase":"PHASE2","title":"VEL-101 to Prevent Rejection After Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Veloxis Pharmaceuticals","startDate":"2026-07","conditions":"Transplantation, Kidney","enrollment":120},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT03373227","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2017-12-04","conditions":"Heart Transplant Rejection, Graft Failure, Compliance, Patient","enrollment":50},{"nctId":"NCT05242315","phase":"PHASE4","title":"Extended-Release Tacrolimus Following Liver Transplantation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-05-15","conditions":"Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction","enrollment":94},{"nctId":"NCT03726307","phase":"PHASE1","title":"Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angus W. Thomson PhD DSc","startDate":"2019-04-10","conditions":"Kidney Transplant, Renal Transplant Recipients","enrollment":28},{"nctId":"NCT06235892","phase":"PHASE3","title":"Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Organ Grafts","enrollment":332},{"nctId":"NCT04561986","phase":"PHASE3","title":"TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Antibody-mediated Rejection","enrollment":50},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT05073822","phase":"PHASE1, PHASE2","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2023-02-20","conditions":"Renal Transplant Rejection, Renal Transplant Infection","enrollment":""},{"nctId":"NCT04903054","phase":"PHASE2","title":"Selective CD28 Blockade in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-01-10","conditions":"Kidney Transplantation, Renal Transplant Recipients","enrollment":""},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT03591380","phase":"PHASE2","title":"CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-14","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT02217410","phase":"PHASE1, PHASE2","title":"CCFZ533X2201 - PoC Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-05","conditions":"Kidney Transplantation","enrollment":59},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prograf (SOC)","genericName":"Prograf (SOC)","companyName":"University of Alberta","companyId":"university-of-alberta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prograf (tacrolimus) inhibits calcineurin phosphatase, suppressing T-cell activation and proliferation to prevent organ rejection. Used for Prevention of organ rejection in kidney transplant recipients, Prevention of organ rejection in heart transplant recipients, Prevention of organ rejection in liver transplant recipients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}